Quantcast

Latest Pulmonology Stories

2014-10-06 12:29:10

Annual Award from FierceMedicalDevices Names 15 Top Innovative and Market-Disrupting Medical Device Companies IRVINE, Calif., Oct. 6, 2014 /PRNewswire/ -- Breathe Technologies, a developer and manufacturer of innovative medical technologies for patients with respiratory insufficiency diseases and neuromuscular diseases, announced today that it has been named to the 2014 FierceMedicalDevices Fierce 15. The designation is awarded to 15 companies selected by FierceMedicalDevices editors...

Potential New Target To Treat Asthma Attacks Brought On By Colds
2014-10-06 03:05:56

Provided by Francesca Davenport, Imperial College London Researchers have identified a molecular mechanism that could explain why the common cold can bring on life-threatening asthma attacks. Published today in Science Translational Medicine, the findings indicate this may be a potential target for new drugs that could be more effective than existing treatments. Viruses that infect the airways are the most common cause of asthma attacks, accounting for 80-90 per cent of cases. The...

2014-10-01 23:03:45

Asthma is a complex illness and new treatments are always being considered. The pulmonary harmonica has been designed to improve breathing with no musical talent required, and the potential benefits for people with COPD, asthma, allergies, and cystic fibrosis are being explored. Sarasota, FL (PRWEB) October 01, 2014 While attending a recent Association of Asthma Educators conference in San Antonio, Dana Keller, PhD, inventor of the Pulmonica Pulmonary Harmonica, spoke with researchers,...

2014-10-01 08:31:45

WARRINGTON, Pa., Oct. 1, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that the Company has been awarded a Phase II Small Business Innovation Research Grant (SBIR) valued at up to $3.0 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of the Company's aerosolized KL(4) surfactant as a medical countermeasure to mitigate acute and chronic/late-phase...

2014-09-30 00:21:34

TARRYTOWN, N.Y. and PARIS, Sept. 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. "These data suggest the potential of...

Lung Flute Helps COPD Patients Breathe Easier: Study
2014-09-29 03:37:55

By Ellen Goldbaum, University at Buffalo Patients with chronic obstructive pulmonary disease (COPD) report improved symptoms and health status when they use a hand-held respiratory device called the Lung Flute®, according to a new study by the University at Buffalo. Usually caused by smoking, COPD, which includes chronic bronchitis and emphysema, is the third leading cause of death in the US. The Lung Flute, manufactured by Medical Acoustics, (Buffalo), uses sound waves to break up...

2014-09-25 08:27:29

Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva® Respimat® (tiotropium bromide) inhalation spray for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD...

2014-09-21 23:01:40

LifeScienceIndustryResearch.com adds “Flovent (Asthma) – Forecast and Market Analysis to 2023” to its store. Obtain sales forecast for Flovent from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia). Dallas, Texas (PRWEB) September 21, 2014 Originally approved by the Food and Drug Administration (FDA) in 1996, GSK’s Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for...

2014-09-21 23:00:47

LifeScienceIndustryResearch.com adds “Spiriva (Asthma) – Forecast and Market Analysis to 2023” to its store. Detailed information on Spiriva including product description, safety and efficacy profiles as well as a SWOT analysis. Dallas, Texas (PRWEB) September 22, 2014 The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs),...

2014-09-21 23:00:17

LifeScienceIndustryResearch.com adds “Pulmicort (Asthma) – Forecast and Market Analysis to 2023” to its store. Detailed information on Pulmicort including product description, safety and efficacy profiles as well as a SWOT analysis. Dallas, Texas (PRWEB) September 22, 2014 AstraZeneca’s Pulmicort is an ICS therapy that was originally launched in 1997, and is used prophylactically for the maintenance treatment of asthma in children and adults. Its active ingredient, budesonide, is...


Latest Pulmonology Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »
Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related